SecBot SecBot

CRBU

Caribou Biosciences, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001619856 Biotech & Drug Discovery
$0.3530 −0.01 (−2.49%)
Nov 16 4:00 PM ET · prev $0.3620
Market cap
$41.1M
Nano cap
Consensus
Buy
67% Buy or better · 12 analysts
Median target
$1.00
+183% · range $1.00–13.00
1 year
−81.3%
from $1.89 · Nov 17
30 days
−23.9%
from $0.4640
52-week range
$0.3530–2.43
at the low
Avg volume 20D
2.16M
shares / day
Short interest
14.89M
≈13.8% of shares · +18.6%
Days to cover
6.0
at average volume
Insider net
−$47.5K
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $47.5K.

  • InstitutionsBULLISH

    Q3 2026: 20 added (0 new), 9 trimmed or exited.

  • AnalystsBULLISH

    8 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.360 → −$0.278 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +18.6% to 14.89M shares. 6.0 days to cover, ≈13.8% of shares.

  • TrendDOWNTREND

    56% below its 50-day average. New closing low $0.3530 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 6.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdDOUBLED1,119,690$1.4M
FMR LLCADD1,075,393$1.4M
UBS Group AGADD824,282$1.0M
MORGAN STANLEYDOUBLED665,754$845.5K
MARSHALL WACE, LLPADD575,216$730.5K
Nuveen, LLCADD204,107$259.2K
Quadrature Capital LtdADD147,435$187.2K
BARCLAYS PLCDOUBLED129,962$165.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 67% rate it Buy or better
Strong Buy3Buy5Hold4Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +183%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Oct 7, 2026Brookline Capital
DOWNGRADE
DOWNGRADEHold
Oct 7, 2026RBC Capital
DOWNGRADE
DOWNGRADESector Perform
Oct 7, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Aug 14, 2026B of A Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$47.5K
sold · 4 insiders
DateInsiderTypeValue
Feb 25, 2026
Kelly Timothy P
Chief Technology Officer
Feb 25, 2026
SELL$12.0K
Feb 24, 2026
MCCLUNG BARBARA G
Chief Legal Officer
Feb 24, 2026
SELL$13.6K
Feb 24, 2026
Kelly Timothy P
Chief Technology Officer
Feb 24, 2026
SELL$6.2K
Feb 24, 2026
Khan Ruhi Ahmad
Chief Business Officer
Feb 24, 2026
SELL$13.6K
Feb 24, 2026
Albertson Tina M.
Chief Medical Officer
Feb 24, 2026
SELL$2.1K
Feb 20, 2026
GUGGENHIME ANDREW
Director
Feb 20, 2026
AWARD45,000 sh
Feb 20, 2026
Sacks Natalie
Director
Feb 20, 2026
AWARD45,000 sh
Feb 20, 2026
MCCLUNG BARBARA G
Chief Legal Officer
Feb 20, 2026
AWARD202,500 sh

Earnings setup

Estimates
−$0.28
EPS estimate, this quarter
+23%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.28-$0.34–-$0.20+23.4%$20.6M
Next QNoneNoneNo data$0.00
Current FY-$1.03-$1.10–-$0.94+11.9%$25.7M
Next FY-$0.65-$1.23–-$0.32+45.4%$24.8M

Short side

FINRA· Oct 30, 2026
14,892,848
shares short
+18.6%
vs prior settlement
6.0
days to cover
≈13.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

11 filings · 2 press releases · 1 bullish · 2 bearish · 2 mixed · 6 neutral
All CRBU filing & press-release reports (13)